
    
      To better understand the direct effects of paricalcitol on anemia in patients with chronic
      kidney disease (stage 3-5), we conducted a pilot trial in 60 patients who were randomly
      allocated equally to 2 groups to receive or not paricalcitol orally for 6 months.
    
  